Study of the potential pharmacodynamic antagonism of RU 41 656 on scopolamine and triazolam impairment in healthy subjects

Abstract

The potential improvement on attention and memory of a single oral does of R U 41 656, and the potential antagonism of the deficits of these functions induced by oral administration of scopolamine 1 mg and triazolam 0.5 mg, have been investigated in a six-period, placebo-controlled, double-blind, crossover study involving 12 healthy young volunteers. The effects of the compounds were evaluated by objective test (Buschke selective reminding test, CFF, simple and multiple-choice reaction time, tapping, arithmetical calculation, DSST) and subjective measurements (visual analogue scale, side-effects questionnaire). Measurements were taken before treatment and 2, 4 and 7 h after R U 41 656 intake. Neither placebo alone nor R U 41 656 alone modified the performances of these subjects. Under the experimental conditions of the trial, scopolamine given orally did not cause the disturbances of attention and memory usually described. On the contrary, triazolam caused a pronounced impairment of vigilance and memory. R U 41 656 did not antagonize the sedative effects of triazolam, but partially attenuated its amnesic effects.

Tropane alkaloids

“…156 Scopolamine has an effect on visual evoked potentials in ageing and dementia.157 Pharmacodynamic antagonism of Ru 41 656 on scopolamine and triazolam impairment has been studied. 158 Predatory behaviour pattern in cats is altered by 4.3.2. Hyperactivity ; Efect on Slowing Cholinergic and dopaminergic agents contribute to scopolamine-induced hyperactivity in mice.160 P-Glucuronide and sulfate show conjugation of scopolamine and glycopyrrolate.…”